eClinical Tech News

Connect Biopharma reported a cluster of catalysts around its IL-4Rα antibody rademikibart: rapid-onset bronchodilation in a phase 1 intravenous...

Fortress Biotech is exiting 2025 and entering 2026 with a string of monetization events that reshape its balance sheet...

Cue Biopharma has appointed Lucinda Warren as interim president and CEO, effective March 26, 2026, following the departure of...

AnaptysBio will spin off its biopharma operations into First Tracks Biotherapeutics, expected to list as TRAX, with a target...

Humacyte reported fourth-quarter and full-year 2025 results and advanced multiple commercial and clinical fronts for its bioengineered vascular conduit,...

Werewolf Therapeutics has begun a strategic alternatives process, retaining Piper Sandler to evaluate options that include a sale, merger,...

Leonabio has acquired an exclusive global license (excluding Asia and select Middle Eastern countries) to develop and commercialize lasofoxifene,...

DBV Technologies closed 2025 with momentum behind its Viaskin Peanut program, reporting positive phase 3 results in children aged...

Rani Therapeutics has moved its oral biologics platform from promise to clinical testing, initiating a Phase 1 study of...

Spero Therapeutics’ partner GSK has resubmitted the New Drug Application for tebipenem HBr, an oral carbapenem for complicated urinary...